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Abstract
Aims/hypothesis The nuclear receptor peroxisome proliferator-
activated receptor gamma (PPARγ) is an important gene regu-
lator in glucose and lipid metabolism. Unfortunately, PPARγ-
activating drugs of the thiazolidinedione class provoke adverse
side effects. As recently shown, amorfrutin A1 is a natural
glucose-lowering compound that selectively modulates
PPARγ. In this study we aimed to characterise, in vitro, a large
spectrum of the amorfrutins and similar molecules, which we
isolated from various plants. We further studied in vivo the
glucose-lowering effects of the so far undescribed amorfrutin B,
which featured the most striking PPARγ-binding and pharma-
cological properties of this family of plant metabolites.
Methods Amorfrutins were investigated in vitro by binding
and cofactor recruitment assays and by transcriptional acti-
vation assays in primary human adipocytes and murine
preosteoblasts, as well as in vivo using insulin-resistant
high-fat-diet-fed C57BL/6 mice treated for 27 days with
100 mg kg−1 day−1 amorfrutin B.
Results Amorfrutin B showed low nanomolar binding affin-
ity to PPARγ, and micromolar binding to the isotypes
PPARα and PPARβ/δ. Amorfrutin B selectively modulated
PPARγ activity at low nanomolar concentrations. In insulin-
resistant mice, amorfrutin B considerably improved insulin
sensitivity, glucose tolerance and blood lipid variables after
several days of treatment. Amorfrutin B treatment did not
induce weight gain and furthermore showed liver-protecting
properties. Additionally, amorfrutins had no adverse effects
on osteoblastogenesis and fluid retention.
Conclusions/interpretation The application of plant-derived
amorfrutins or synthetic analogues thereof constitutes a
promising approach to prevent or treat complex metabolic
diseases such as insulin resistance or type 2 diabetes.
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BGLAP Bone γ-carboxyglutamate protein
CBP CREB-binding protein
CHO Chinese hamster ovary
DIO Diet-induced obesity
DRIP Vitamin D receptor interacting protein
EC50 Half-maximal effective concentration
HFD High-fat diet
HOMA-IR HOMA of insulin resistance
IPIST Intraperitoneal insulin sensitivity test
Ki Binding affinity constant
NCoR Nuclear receptor corepressor
PGC1 PPARγ coactivator 1
Electronic supplementary material The online version of this article
(doi:10.1007/s00125-013-2920-2) contains peer-reviewed but unedited
supplementary material, which is available to authorised users.
C. Weidner : S. J. Wowro :A. Freiwald :A. Witzke :M. Kliem :
S. Sauer (*)
Otto Warburg Laboratory, Max Planck Institute
for Molecular Genetics, Ihnestrasse 63-73,
14195 Berlin, Germany
e-mail: sauer@molgen.mpg.de
C. Weidner :A. Witzke
Department of Biology, Chemistry, and Pharmacy,
Free University of Berlin, Berlin, Germany
K. Kawamoto : F. C. Schroeder
Boyce Thompson Institute and Department of Chemistry
and Chemical Biology, Cornell University, Ithaca, USA
K. Siems : L. Müller-Kuhrt
AnalytiCon Discovery, Potsdam, Germany
Diabetologia (2013) 56:1802–1812
DOI 10.1007/s00125-013-2920-2
PPAR Peroxisome proliferator-activated receptor
PRIP PPAR-interacting protein
RAP250 Nuclear receptor coactivator RAP250
RGZ Rosiglitazone
Si Small interfering
SPPAR[γ]M Selective peroxisome proliferator-activated
receptor [γ] modulator
TRAP220 Thyroid hormone receptor-associated protein
complex 220 kDa component
TR-FRET Time-resolved fluorescence resonance energy
transfer
TZD Thiazolidinedione
WAT White adipose tissue
Introduction
Faced by an alarming global increase in the incidence of
obesity and type 2 diabetes, there is an urgent need to
develop effective treatment and prevention strategies [1].
Besides lifestyle interventions, the application of safe pre-
ventive drugs or tailored food supplements may help to
combat the current epidemic of increasing insulin resistance,
a hallmark of type 2 diabetes [2].
The peroxisome proliferator-activated receptor gamma
(PPARγ) plays a central role in glucose and lipid homeostasis,
and pharmacological modulation of this nuclear receptor is an
established strategy to treat insulin resistance and dyslipidaemia
[3]. However, strongly activating PPARγ drugs such as the
thiazolidinediones (TZDs) were withdrawn from the market or
restricted in their prescription because they provoke adverse side
effects such as weight gain, oedema, osteoporosis, cancer and
heart failure [4, 5]. Rosiglitazone (RGZ; Avandia) effectively
improves insulin sensitivity by fully activating PPARγ-
regulated gene expression in various tissues, but this non-
specific transcriptional activation appears to be linked to the
unwanted side effects. However, partial agonism of PPARs by
selective PPARγ modulators (SPPARγMs) can promote a
differential cofactor recruitment profile, leading to specific
patterns of gene expression that maintain the glucose-
lowering potential of full PPARγ agonists but without induc-
ing the side effects described above. Thus, the use of
SPPARγMs is a promising approach for developing glucose-
lowering agents with an acceptable safety profile [6–8]. Com-
bined activation of PPARα, PPARβ/δ and PPARγ by a single
compound has further been proposed as an innovative thera-
peutic approach that may result in glucose-lowering effects and
improved lipid profiles with fewer side effects [9].
We recently reported the characterisation of four
amorfrutins, a family of phenyl terpenoid natural products,
derived from a compound library [10]. Here, we explore a
wide spectrum of naturally available amorfrutins and related
compounds, isolated from various natural resources. We
identified amorfrutin B as a novel natural PPARγ modulator
with greatly increased binding affinity compared with values
recently published for other amorfrutins. Amorfrutin B shows
potent glucose-lowering effects in high-fat-diet (HFD)-fed
mice comparable with those of RGZ, but without inducing
any of the side effects typically associated with the TZDs or
other strong synthetic PPARγ activators.
Methods
Materials Compounds were purchased as described in the
electronic supplementary material (ESM) Methods.
PPAR binding, cofactor recruitment and transcriptional ac-
tivation assays Binding of natural products was quantified
as described in the ESM Methods.
Cell culture For details, see the ESM Methods.
PPARγ knockdown Specificity of PPARγ modulation was
investigated in small interfering (si)RNA-mediated PPARγ-
knockdown in human primary adipocytes, as described in
the ESM Methods.
RNA purification, cDNA synthesis and quantitative real-
time PCR See the ESM Methods for further details. Primer
sequences are summarised in ESM Table 1.
Pharmacokinetics Pharmacokinetic experiments were
performed at Charles River (Edinburgh, UK). Briefly, 18
male C57BL/6 mice were orally given amorfrutin B,
100 mg/kg body weight, in 1% (wt/vol.) carboxymethylcel-
lulose. Terminal blood samples were collected after 0.5, 1,
2, 4, 8 and 24 h after dosing and analysed using liquid
chromatography (LC)-MS/MS.
Animal studies Animal studies were approved by the State
Office of Health and Social Affairs, Berlin, Germany, and were
carried out according to internationally approved guidelines. All
animals were singly housed under temperature-, humidity- and
light-controlled conditions (22°C, 50% humidity, 12 h light/12 h
dark cycle). Mice had ad libitum access to food and water. Mice
and food were weighed regularly. Male 6 week-old C57BL/6
mice were fed for 12 weeks with an HFD (D12492, kJ compo-
sition 60% fat, 19% protein, 21% carbohydrate, 25.3 MJ/kg;
ssniff, Soest, Germany) to induce obesity and insulin resistance.
Prior to treatment, mice were weighed and distributed uniformly
to three groups (n=10–13 each).Micewere fed over 4weekswith
anHFDwithout compound (vehicle), with 4mg kg−1 day−1 RGZ
or with 100mg kg−1 day−1 amorfrutin B incorporated in the food.
After 15 days of treatment an intraperitoneal insulin
sensitivity test (IPIST) was performed. Mice were fasted
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overnight and then had ad libitum access to food for 1 h before
the test. Insulin (Sigma-Aldrich, Taufkirchen, Germany) at
1.5 U/kg body weight was injected i.p. Blood was taken from
the tail vein at the indicated time points and blood glucose was
analysed in a Hemocue B-Glucose analyser (Hemocue,
Großostheim, Germany). Whole blood was further collected
using Microvette lithium-heparin coated capillary tubes
(CB300, Sarstedt, Nürnbrecht, Germany). After centrifuga-
tion for 5 min at 2,000 g and 4°C, plasma was collected and
stored at −80°C for subsequent measurements.
After 22 days of feeding an OGTT was carried out. Mice
were fasted overnight before being subjected to an oral
glucose dose of 2 g/kg body weight (Sigma-Aldrich). Blood
was taken from the tail vein at the indicated time points and
examined as described above.
After 27 days of dosing, fasted mice were killed by
cervical dislocation. Hematocrit was measured by weighting
of blood samples before and after plasma separation and is
given in wt/wt %. Plasma and tissues were collected and
stored at −80°C before use.
Metabolic variable measurements Blood glucose was
analysed in a Hemocue B-Glucose analyser. Plasma glucose
was measured using the Amplex Red Glucose Assay Kit
(Life Technologies, Carlsbad, CA, USA). Plasma
triacylglycerols, NEFA, HDL- and LDL-cholesterol and
plasma alanine transaminase (ALT) were determined with
colorimetric quantification kits (Biovision, Milpitas, CA,
USA). Plasma β-hydroxybutyrate was analysed colorimet-
rically (Cayman Chemical, Ann Arbor, MI, USA). Insulin
(Insulin Ultrasensitive EIA, ALPCO, Salem, NH, USA), T3,
T4 (Calbiotech, San Diego, CA, USA), osteocalcin (bone γ-
carboxyglutamate protein [BGLAP], ABIN415574,
antibodies-online, Aachen, Germany) and FGF21
(BioVendor, Heidelberg, Germany) were determined in
plasma samples using ELISA. Whole-blood haemoglobin
(Hemoglobin Colorimetric Assay Kit, Cayman Chemical)
was analysed for investigation of haemodilution. All assays
were performed according to the manufacturer’s instruc-
tions. HOMA-insulin resistance (IR) was determined
according to HOMA-IR=fasting blood glucose (mmol/l)×
fasting insulin (pmol/l)/156.
Immunoblotting PPARγ-Ser273 phosphorylation was
investigated as described in ESM Methods.
Statistical analyses Data are presented as mean ± SEM if
not otherwise denoted. Statistical tests were performed in
GraphPad Prism 5.0 (La Jolla, CA, USA). For comparison
of two groups, statistical significance was examined by
unpaired two-tailed Student’s t test if not otherwise stated.
For multiple comparisons, data were analysed by one-way
ANOVA with subsequent Dunnett’s post hoc test. A p
value≤0.05 was defined as statistically significant. Further
details are described in ESM Methods.
Results
Amorfrutin B is the most selective and potent SPPARγM of
various natural amorfrutins and partially recruits important
transcriptional cofactors We first analysed a series of
amorfrutins isolated from the edible fruits of Amorpha
fruticosa and edible roots of Glycyrrhiza foetida, or other
natural resources, using in vitro binding assays. In addition to
the four recently described amorfrutins [10], we discovered 34
amorfrutins and related natural products from 38 candidate
compounds (ESM Fig. 1) with binding affinities for PPARγ
ranging from 19 nmol/l to 6 μmol/l (ESM Fig. 2 and ESM
Table 2). In agreement with our structural analyses of these
natural products [11], amorfrutin B (Fig. 1a) had the lowest,
nanomolar, binding affinity constant (Ki) to PPARγ (Ki=
19 nmol/l; Table 1) similar to the standard PPARγ-targeting
drug RGZ (Ki=7 nmol/l; Table 1), and 12 times lower than the
initially described amorfrutin A1 [10]. Additionally, the
amorfrutins bound to the subtypes PPARα and PPARβ/δ
(ESM Figs 3, 4 and ESM Table 2). Amorfrutin B revealed
potent binding to PPARα (Ki=2,624 nmol/l, Table 1) and
PPARβ/δ (Ki=1,782 nmol/l, Table 1) with low-micromolar
affinity, suggesting that this compound may also modulate the
activity of these PPARs. Such partial pan-PPAR modulation
may facilitate the concomitant treatment of diabetes-associated
disorders, but is difficult to trace mechanistically because of the
involvement, and potential cross-talk, of various tissues.
We further explored the transcriptional activation poten-
tial of the amorfrutins using reporter gene assays. We ob-
served PPARγ activation, with half-maximal effective
concentration (EC50) values ranging from 25 nmol/l to
6.9 μmol/l and transactivation efficacies ranging from 5%
to 79% relative to RGZ (ESM Fig. 5 and ESM Table 2).
Once more, amorfrutin B showed nanomolar effective con-
centrations (EC50=73 nmol/l) and reduced maximal PPARγ
activation (efficacy=25%, Fig. 1b and Table 1). In contrast
to the full PPARγ agonist RGZ, amorfrutins only partially
induced transcriptional activation of PPARγ, suggesting
that these natural products represent a new chemical class
of selective PPAR modulators (SPPARM).
Transcriptional activation of the PPARα subtype was
additionally tested in reporter gene assays, with amorfrutin
B revealing EC50 and efficacy values of 906 nmol/l and
61%, respectively (Fig. 1c and Table 1), and a range from
157 nmol/l to 4.7 μmol/l and 13% to 68%, respectively, for
the related compounds (ESM Fig. 6 and ESM Table 2).
Despite activation of the PPARβ/δ subtype by amorfrutin
B at nanomolar concentrations (EC50=740 nmol/l), efficacy
of PPARβ/δ activation was low (3%; Fig. 1d and Table 1).
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Table 1 Binding and activation
of PPARs by amorfrutin B
Binding affinity (Ki) values were
obtained by using competitive
time-resolved fluorescence reso-
nance energy transfer (TR-
FRET) assays; EC50 and efficacy
values were determined from
reporter gene assays. Efficacy is
the maximum activation relative
to the reference agonist
ND, not determined; ref., reference
Receptor Amorfrutin B RGZ GW7647 GW0742
PPARα
Ki (nmol/l) 2,624 [ref. 11] ND 1 [ref. 10] ND
EC50 (nmol/l) 906 ND 0.3 ND
Efficacy (%) 61 ND 100 ND
PPARβ/δ
Ki (nmol/l) 1,782 [ref. 11] ND ND 0.4 [ref. 10]
EC50 (nmol/l) 740 ND ND 0.2
Efficacy (%) 3 ND ND 100
PPARγ
Ki (nmol/l) 19 [ref. 11] 7 [ref. 10] ND ND
EC50 (nmol/l) 73 4 ND ND
Efficacy (%) 25 100 ND ND
Fig. 1 Amorfrutin B induces partial activation of PPARs. (a) Chem-
ical structure of amorfrutin B. (b) Transcriptional activation of PPARγ
by amorfrutin B (black triangles) or RGZ (grey squares) in a reporter
gene assay. (c) Transcriptional activation of PPARα by amorfrutin B
(black triangles) or GW7647 (grey circles) in a reporter gene assay. (d)
Transcriptional activation of PPARβ/δ by amorfrutin B (black trian-
gles) or GW0742 (grey diamonds) in a reporter gene assay. (e–i)
Recruitment of transcriptional cofactor peptides to PPARγ-LBD titrat-
ed with amorfrutin B (black triangles) or RGZ (grey squares). Binding
of cofactor peptides was measured by time-resolved fluorescence res-
onance energy transfer (TR-FRET). Recruitment is represented relative
to RGZ. Peptides are derived from coactivators CBP (e), PGC1α (f),
TRAP220/DRIP (g), PRIP/RAP250 (h) or corepressor NCoR (i). Data
are expressed as mean ± SD (n=3)
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Furthermore, amorfrutin B only partially induced recruit-
ment of important transcriptional cofactors including
CREB-binding protein (CBP), PPARγ coactivator 1
(PGC1)α, thyroid hormone receptor-associated protein
complex 220 kDa component (TRAP220)/vitamin D recep-
tor interacting protein (DRIP) and PPAR-interacting protein
(PRIP)/nuclear receptor coactivator 250 (RAP250) to
PPARγ (Fig. 1e–i, Table 2 and ESM Fig. 7). In contrast,
amorfrutin B reduced binding of the corepressor nuclear
receptor corepressor 1 (NCoR) with an IC50 value similar
to RGZ (60 nmol/l vs 23 nmol/l with RGZ), but with lower
maximal dissociation efficacy (61% vs RGZ, Fig. 1i,
Table 2). This was similar for other amorfrutin variants
(ESM Fig. 7 and ESM Table 2). These results indicate that
amorfrutin B is a high-affinity SPPARM with potential to
exhibit strong glucose-lowering properties without provok-
ing side effects associated with full PPARγ activation.
Amorfrutin B selectively activates PPARγ in primary human
adipocytes Consistent with partial PPARγ activation, in hu-
man primary adipocytes amorfrutin B induced the expression
of adipogenesis-related genes such as CCAAT/enhancer bind-
ing protein α and β (CEBPA and CEBPB) and the fatty acid
binding protein 4 (FABP4) much less strongly than RGZ
(Fig. 2a), indicating alleviated adipocyte differentiation. In
contrast to RGZ, amorfrutin B further showed reduced RNA
expression of the cortisol generating hydroxysteroid (11-β)
dehydrogenase 1 (HSD11B1), which is linked to central obe-
sity [12]. Additionally, amorfrutin B treatment led to decreased
transcription of pyruvate dehydrogenase kinase 4 (PDK4),
encoding a glycerogenesis-activating enzyme linked to excess
lipid storage in adipocytes [13]. However, amorfrutin B treat-
ment also resulted in increased phosphodiesterase 3B
(PDE3B) expression, which is responsible for beneficial
NEFA release in TZD-treated mice [14]. No treatment had
any effects on NCOR1 gene expression (ESM Fig. 8).
As secretion of endocrine factors by adipose tissue plays a
pivotal role in systemic metabolism, we further investigated
the expression of important adipokines in treated human
adipocytes. Amorfrutin B treatment led to increasing
transcription of the beneficial adipokines adiponectin
(ADIPOQ), fibroblast growth factor 21 (FGF21) and
Table 2 Cofactor recruitment profile of amorfrutin B bound to PPARγ






CBP 12 100 111 26
PGC1α 57 100 126 30
TRAP220/DRIP 36 100 273 8
PRIP/RAP250 41 100 14 27
NCoR 23 100 60 61
Effective (EC50) or inhibitory (IC50) concentrations and efficacy of
amorfrutin B-induced recruitment of cofactor peptides to PPARγ were
obtained using a TR-FRET assay. Efficacy is the maximum recruitment
relative to the RGZ-induced activation of PPAR
Fig. 2 Gene expression profile of amorfrutin B and RGZ in primary
human adipocytes. Cells were treated for 24 h with 10 μmol/l RGZ
(grey bars) or 10 μmol/l amorfrutin B (black bars) and expression of
known PPARγ target genes (a) and adipokines (b) was analysed by
quantitative PCR. (c) Primary human adipocytes were transfected with
PPARγ siRNA (hatched bars) or control siRNA (unhatched bars) and
were treated with either 10 μmol/l RGZ (grey bars), 10 μmol/l
amorfrutin B (black bars) or vehicle only (white bars) for 24 h.
RNA expression was analysed by quantitative PCR. Data are
expressed as mean ± SEM (n=3–4/group). *p≤0.05, **p≤0.01
and ***p≤0.001 vs vehicle. AB, amorfrutin B; neg., negative;
NS, not significant
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angiopoietin-like 4 (ANGPTL4), similar to RGZ treatment,
but we observed no regulation of leptin (LEP) transcription
(Fig. 2b). Furthermore, amorfrutin B resulted in reduced
expression of pro-inflammatory angiopoietin-like 2
(ANGPTL2), retinoic acid receptor responder 2 (RARRES2)
and adipsin (complement factor 2 [CFD]) (Fig. 2b). In
summary, these data indicate potential glucose-lowering effects
with, presumably, lower susceptibility to adipose-derived body
weight gain in vivo with amorfrutin B treatment.
Knockdown of PPARγ in these cells led to a significant
reduction of amorfrutin B-induced gene expression (Fig. 2c),
corroborating specific modulation of PPARγ-derived tran-
scription in human adipocytes.
Pharmacokinetic profile of amorfrutin B in C57BL/6
mice To start exploring the pharmacological profile of
amorfrutin B, C57BL/6 mice were orally challenged once
with a loading dose of 100 mg/kg amorfrutin B (Fig. 3a,
Table 3). Administration of amorfrutin B led to a fast plasma
concentration peak, indicating a high bioavailability of that
natural product. Amorfrutin B was almost completely elim-
inated within 24 h of the dose, with an elimination half-life
of about 2 h (Table 3). Amorfrutin B and amorfrutin A1 [10]
showed similar pharmacokinetic properties (Table 3).
Amorfrutin B has strong glucose-lowering effects and
considerably improves dyslipidaemia in mice with diet-
induced obesity To characterise amorfrutin B in a dia-
betic obese animal model, we treated HFD-fed C57BL/6
mice for 4 weeks with 100 mg kg−1 day−1 amorfrutin B,
4 mg kg−1 day−1 RGZ or vehicle only. After 2 weeks
amorfrutin B-treated mice exhibited reduced concentra-
tions of fasting blood glucose (Fig. 3b) and fasting
plasma insulin (Fig. 3c), equal to or more reduced than
in RGZ-treated mice. Amorfrutin B- and RGZ-treated
mice showed equal reductions in insulin resistance as
determined by homeostatic modelling (Fig. 3d). In
OGTT (Fig. 3e, f) and IPIST (Fig. 3g) amorfrutin B
treatment resulted in reductions in insulin resistance and
glucose intolerance similar to those achieved with RGZ.
Amorfrutin B strongly decreased the concentration of
triacylglycerols and NEFA in the plasma of HFD-fed mice,
comparable with RGZ (Fig. 4). After 4 weeks of treatment,
amorfrutin B and RGZ both reduced fasting plasma levels of
Fig. 3 Effect of amorfrutin B treatment in insulin-resistant DIO mice.
(a) Pharmacokinetic profile of amorfrutin B after oral administration in
C57BL/6 mice. Data are expressed as mean ± SEM (n=3). (b) Fasting
blood glucose of DIO mice after 15 days of treatment with vehicle
(body weight=41.7±1.1 g), RGZ (body weight=41.2±1.5 g) or
amorfrutin B (body weight=35.7±1.4 g). (c) Fasting plasma insulin
of DIO mice after 15 days of treatment. (d) Effect of treatment for
15 days on insulin resistance determined by HOMA-IR. (e, f) Glucose
and insulin concentrations during OGTT after 22 days of treat-
ment with vehicle (white circles/bars, body weight=39.9±1.0 g
[n=13]), RGZ (grey squares/bars, body weight=39.9±1.5 g [n=8–
10]) or amorfrutin B (black triangles/bars, body weight=34.4±
1.3 g [n=13]). (g) Glucose levels during the IPIST after 15 days
of treatment. Data are expressed as mean ± SEM. *p≤0.05, **p≤
0.01 and ***p≤0.001 vs vehicle. AB, amorfrutin B; AUCi, inverse
AUC; VEH, vehicle
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triacylglycerols by 25% (Fig. 4a). Fasting concentrations of
deleterious plasma NEFA were decreased by 29% with
amorfrutin B and 40% with RGZ treatment (Fig. 4b).
Based on the results described above, the physiological
effects of amorfrutin B treatment seemed to be largely con-
trolled via nanomolar activation of PPARγ and differential
expression of its target genes in the adipocytes. In visceral
white adipose tissue (WAT), amorfrutin B significantly in-
creased the expression of PGC1α and PGC1β (Ppargc1a
and Ppargc1b) (twofold each, ESM Fig. 9), indicating im-
proved mitochondrial biogenesis and fatty acid breakdown.
Amorfrutin B and RGZ equally increased expression of
adiponectin (Adipoq) and uncoupling protein 3 (Ucp3), by
approximately twofold each, but only RGZ clearly boosted
Ucp1 expression (20-fold vs 1.6-fold, ESM Fig. 9).
We investigated further in vivo gene expression to explore
potential additional physiological effects derived from regula-
tion via the liver and skeletal muscle. In liver, in contrast to
RGZ, amorfrutin B only partly regulated gluconeogenic genes
(ESM Fig. 10a). Both RGZ and amorfrutin B showed a 25%
increase in transcription ofPpargc1a but in general amorfrutin
B treatment resulted in minor changes in the expression of
fatty acid oxidation genes (ESM Fig. 10b). The most promi-
nent difference between RGZ- and amorfrutin B-treated livers
was pyruvate dehydrogenase 4 (Pdk4), which was highly
activated only in RGZ-treated mice (+96% vs vehicle, ESM
Fig. 10b). These data confirm the effects observed in human
primary adipocytes (Fig. 2a), suggesting a switch between
carbohydrate and lipid metabolism that may play a role in
the different mechanisms between RGZ and amorfrutin B.
As ketone body metabolism is involved in diabetes and
obesity, we further analysed the expression of ketogenic genes
in the livers of these mice. Both RGZ and amorfrutin B
activated genes of ketone metabolism, with a striking increase
in expression of 3-hydroxy-3-methylglutaryl-CoA synthase 1
(Hmgcs1) in amorfrutin B-treated mice (+123%, ESM
Fig. 10c). However, plasma levels of β-hydroxybutyrate were
not significantly changed after treatment (ESM Fig. 10d). To
further explore potential PPARβ/δ-induced insulin-sensitising
effects in skeletal muscle, we analysed the expression of var-
ious target genes but could not detect any amorfrutin-induced
differential regulation (ESM Fig. 10e), suggesting a minor role
of the skeletal muscle in the observed glucose-lowering profile
of amorfrutins, which is in agreement with the low PPARβ/δ
activation observed in reporter gene assays (Fig. 1d).
To investigate the role of the peptide hormone fibroblast
growth factor 21 (FGF21) in the observed metabolic im-
provement, we additionally determined Fgf21 expression in
WAT and liver, and circulating FGF21 plasma levels. As
described for TZDs [15], RGZ induced Fgf21 gene expres-
sion in liver and adipose tissue (ESM Fig. 11) and strikingly
increased FGF21 plasma levels (ESM Fig. 11). However,
amorfrutin B completely failed to induce expression and
secretion of FGF21, suggesting alternative PPARγ activa-
tion to the described TZD–FGF21 autocrine loop. We fur-
ther explored if the phosphorylation of PPARγ on Ser273 in
WAT [16] might mediate the glucose-lowering effects of
amorfrutin B, but did not observe any significant change at
this phosphorylation site after RGZ or amorfrutin B treat-
ment (ESM Fig. 12).
Amorfrutin B does not induce the adverse side effects asso-
ciated with TZDs As discussed above, PPARγ-targeting
drugs such as RGZ are linked to undesirable side effects.
We therefore tested for potential side effects of amorfrutin B
treatment. Viability and cytotoxicity assays in HepG2 cells
did not reveal any adverse effects up to 32 μmol/l
amorfrutin B (ESM Fig. 13). The potential carcinogenicity
of amorfrutin B was evaluated using a cellular micronucleus
assay. In this assay, the formation of micronuclei during cell
division of Chinese hamster ovary (CHO) cells is observed
microscopically after treatment with potential mutagens.
Amorfrutin B was tested up to a concentration of 32 μmol/l
and showed no genetic toxicity either in the presence (+S9)
or absence (−S9) of metabolic activation by extracts of rat
liver homogenate (Fig. 5a). Of note, amorfrutin B signifi-
cantly reduced the basal formation of micronuclei in the
Table 3 Pharmacokinetics of amorfrutin B and amorfrutin A1 after
single oral administration in male C57BL/6 mice
Variable Amorfrutin B Amorfrutin A1
(100 mg/kg) (100 mg/kg)
Cmax (mg/l) 30.4 42.4
Cmin (mg/l) 0.015 0.015
AUC (mg/l×h) 85.4 111.1
t1/2 (h) 2.3 2.2
ke (h
−1) 0.307 0.318
CL (ml/h) 30.0 26.0
Cmax, maximal concentration; Cmin, minimal concentration; ke, elimi-
nation rate constant; CL, clearance
Fig. 4 Effect of amorfrutin B treatment on plasma lipid variables in
insulin-resistant DIO mice. (a) Fasting plasma triacylglycerols after
27 days of treatment. (b) Fasting plasma NEFA after 27 days of
treatment. Data are expressed as mean ± SEM. *p≤0.05 and **p≤
0.01 vs vehicle. Vehicle, n=13; RGZ, n=10; amorfrutin B, n=12–13.
AB, amorfrutin B; VEH, vehicle
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presence of S9 extract in a concentration-dependent manner,
thus improving genetic integrity. After 4 weeks of treatment,
the livers of RGZ-treated HFD-fed obese mice showed
strongly increased expression of inflammatory markers, in-
dicating macrophage infiltration and potential local inflam-
mation. In contrast, amorfrutin B treatment led to reduced
gene expression of these markers (Fig. 5b), suggesting anti-
inflammatory effects of amorfrutin B treatment in the livers
of HFD-fed mice. In addition, RGZ treatment increased
Fabp4 expression by a factor of 31, indicating increased
lipid storage in the mouse liver, whereas amorfrutin B did
not show any increase in Fabp4 expression (Fig. 5c). Con-
sistently, RGZ elevated plasma ALT levels compared with
untreated HFD-fed mice, indicating liver toxicity. In con-
trast, amorfrutin B treatment led to a reduction of plasma
ALT levels (Fig. 5d), in agreement with the liver-protective
effects previously reported for amorfrutin A1 [10].
Another well-known side effect of TZDs is the impair-
ment of osteoblastogenesis, leading to osteoporosis and
increased fracture risk. Treatment of murine MC3T3-E1
Fig. 5 Amorfrutins do not provoke side effects associated with classic
PPARγ agonists. (a) Analysis of genetic toxicity in the in vitro micro-
nucleus assay in CHO cells in the absence (−S9) and presence (+S9) of
rat liver homogenate extract. CHO cells were treated with different
concentrations of amorfrutin B (n=2), the clastogens mitomycin C (n=
4) or cyclophosphamide (n=4) or vehicle, and micronuclei were
stained with Hoechst dye and counted by fluorescence microscopy.
(b) The livers of DIO mice treated for 4 weeks with RGZ (grey) or
amorfrutin B (black) were analysed by quantitative PCR for expression
of genes associated with macrophage invasion and inflammation (n=
6–9 per group). (c) RNA expression of liver Fabp4 was analysed by
quantitative PCR. (d) Effect of amorfrutin B (n=13) and RGZ (n=10)
or vehicle (n=11) on liver-damage-indicating plasma levels of ALT
after treatment for 4 weeks in DIO mice. (e) MC3T3-E1 preosteoblasts
(hatched bars) were differentiated to osteoblasts in the presence of
vehicle only (white, set to 1), RGZ (grey) or amorfrutin B (black).
The expression of genes involved in osteoblastogenesis was deter-
mined by quantitative PCR. (f) Calcification of differentiated
MC3T3-E1 osteoblasts treated with amorfrutin B (n=6), RGZ (n=4)
and vehicle (n=4) was measured by Alizarin Red S staining. (g) The
effect of amorfrutin B on plasma osteocalcin concentration after treat-
ment for 4 weeks in DIO mice. Osteocalcin was measured by ELISA.
(h) Body weight gain in obese mice after treatment with amorfrutin B
(black triangles, n=13), RGZ (grey squares, n=10) and vehicle only
(white circles, n=13). Data are expressed as mean ± SEM. *p≤0.05,
**p≤0.01 and ***p≤0.001 vs vehicle. AB, amorfrutin B; CP, cyclo-
phosphamide; MMC, mitomycin C; NS, not significant; PRE,
preosteoblasts; VEH, vehicle
Diabetologia (2013) 56:1802–1812 1809
preosteoblasts with RGZ or related TZDs resulted in re-
duced expression of genes involved in osteoblastogenesis,
such as phosphate-regulating gene with homologies to en-
dopeptidases on the X chromosome (Phex), integrin-binding
sialoprotein (Ibsp) and osteocalcin (Bglap) (Fig. 5e). RGZ
treatment led to impaired calcification of bone cells in vitro
as assessed by Alizarin Red S staining (Fig. 5f). In contrast,
treatment with amorfrutin B and related amorfrutins did not
show any reductions in expression of the osteoblast gene set
(Fig. 5e and ESM Fig. 14a) or in mineralisation of bone
cells (Fig. 5f and ESM Fig. 14b) in vitro. In HFD-fed mice,
RGZ increased plasma bone osteocalcin levels by 50%
(Fig. 5g), indicating elevated bone cell turnover. However,
there was no effect on plasma bone osteocalcin levels in
amorfrutin B-treated diet-induced obesity (DIO) mice
(Fig. 5g). Taken together, these results indicate that
amorfrutins do not provoke osteoporosis in mice.
Adverse body weight gain is a frequent side effect of
PPARγ activation due to increased fat storage in WAT.
However, in HFD-fed mice amorfrutin B treatment did not
lead to increased adiposity but, instead, to a beneficial
reduction of body weight gain by approximately 15% com-
pared with HFD-fed mice treated with vehicle control
(Fig. 5h). Given the inconspicuous results from the various
described assays, this observation cannot be explained by
potential compound toxicity. Feeding of amorfrutin B only
had a slight impact on food intake during the first 3 days
(ESM Fig. 15a), and correction for food intake using anal-
ysis of covariance (ANCOVA, ESM Fig. 15b) revealed that
anoretic effects cannot wholly explain the observed reduc-
tion in weight gain after amorfrutin B treatment. To inves-
tigate the potential contribution of the hypothalamic–
pituitary–thyroid axis we measured plasma levels of T3
and T4. Amorfrutin B-treated mice did not show significant
changes in these endocrine hormones (ESM Fig. 15c). In
general, weight reduction may result in improved insulin
sensitivity. Although amorfrutin B-induced effects on body
weight correlated (in part) with improved insulin sensitivity,
ANCOVA clearly showed glucose-lowering effects that
were independent from weight regulation (ESM Fig. 15d).
RGZ has recently been reported to decrease HDL-
cholesterol [17]. After 4 weeks of treatment, RGZ-
treated DIO mice showed a 24% reduction in plasma
HDL-cholesterol, whereas amorfrutin B changed neither
plasma HDL-cholesterol nor LDL-/VLDL-cholesterol
levels (ESM Fig. 16a).
RGZ administration is further associated with the
development of haemodilution and oedema as a result of
fluid retention. Amorfrutin B treatment did not impair
haematocrit (ESM Fig. 16b) or levels of whole-blood
haemoglobin (ESM Fig. 16c) in DIO mice; however, in
our hands RGZ-treated mice did not show any signs of fluid
retention after 4 weeks of treatment.
In summary, these data suggest that natural amorfrutins
are well-tolerated glucose-lowering agents without the side
effects typically associated with clinically used synthetic
PPARγ agonists.
Discussion
We explored the potential of a series of naturally occurring
amorfrutins, including molecules that have not been de-
scribed to date. To our knowledge, amorfrutin B is the plant
molecule with the highest reported binding affinity for
PPARγ, allowing for efficient and selective PPARγ activa-
tion. Treatment with amorfrutins resulted in beneficial
glucose-lowering effects in a murine model of diet-induced
insulin resistance. Compounds derived from natural re-
sources may have additional application areas compared
with synthetic molecules. Our results provide evidence that
natural extracts of amorfrutins derived from edible bioma-
terials such as liquorice could potentially be developed as
phytomedicals or functional food products for the preven-
tion of insulin resistance.
Interestingly, amorfrutin B did not provoke any of the side
effects that are commonly associated with TZDs. PPARγ
agonists such as the TZDs induce weight gain in mice and
humans, a side effect that is counterproductive, particularly
given the causal link between insulin resistance and obesity [2,
18]. In this study, we mainly focused on the glucose-lowering
effects of amorfrutin B. The observed weight-reducing effects
of amorfrutin B might also have contributed to the improve-
ment of insulin sensitivity. The correction for body weight by
using ANCOVA [19] unambiguously demonstrated that
weight-reducing effects alone cannot account for the observed
glucose-lowering effects of amorfrutin B treatment. Corre-
spondingly, we could show that in leptin-receptor-deficient
db/db mice amorfrutin A1 markedly improved insulin sensi-
tivity without affecting body weight [10].
In general, weight regulation can be caused by various
poorly understood mechanisms, including cross-talk between
many tissues. Decreased energy intake was only a minor ob-
served effect in our study (ESM Fig. 15a–b). Elevated energy
expenditure controlled via the hypothalamic–pituitary–thyroid
axis can be a main contributor to overweight loss. However,
using amorfrutin B, neither T3 nor T4 plasma levels were
significantly increased in DIO mice (ESM Fig. 15c). Energy
expenditure can be enhanced by increased physical activity
and/or thermogenesis. Amorfrutin-induced activation of
PPARβ/δ, albeit low, may have resulted in thermogenic effects.
For example, in the WATof amorfrutin B-treated DIO mice we
observed a significant activation of expression of Ppargc1a,
Ppargc1b and Ucp3, and a marginal increase in Ucp1 expres-
sion (ESM Fig. 9), which might have contributed to increased
energy expenditure. However, these effects were not unique to
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amorfrutin-treated mice, as RGZ induced a similar profile with
the exception of an additional striking boost in Ucp1 transcrip-
tion. Future experiments will focus on the dissection of multi-
factorial weight-reducing effects of amorfrutins.
The peptide hormone FGF21 was shown to integrate
several aspects of metabolism in the pathophysiology and
pharmacology of metabolic disorders [20, 21], suggesting a
mechanistic link between the effects of administered PPARγ
TZD ligands and FGF21. As Fgf21-knockout mice were
refractory to both the beneficial insulin-sensitising effects
and the detrimental side effects of RGZ, FGF21 might be a
key mediator of PPARγ actions. However, in amorfrutin B-
treated mice, systemic FGF21 plasma levels as well as local
Fgf21 gene expression were unchanged (ESM Fig. 11). The
fact that amorfrutin B seems to activate PPARγ and improve
insulin sensitivity without significant interaction with FGF21
or without inhibiting the phosphorylation of PPARγ-Ser273
necessitates further mechanistic studies and validation, includ-
ing the search for additional post-translational modifications
of PPARγ and its cofactors.
In addition to the glucose-lowering effects, amorfrutin B
considerably lowered plasma levels of ALT, indicating liver-
protecting properties of amorfrutins. As we have shown recent-
ly, the amorfrutin variant A1 prevented the formation of liver
steatosis in HFD-fed C57BL/6 mice through induction of fatty
acid oxidation and anti-inflammatory gene expression profiles
[10]. These diverse effects might have occurred due to simul-
taneous, more or less efficient activation of PPARγ, PPARα
and PPARβ/δ (Table 1). As a single oral dose of 100 mg/kg in
DIO mice leads to a maximum plasma concentration of 30.4
mg/l and a mean concentration of 3.7 mg/l over 24 h (Fig. 3a,
Table 3), activation of PPARα and PPARβ/δ is of potential
physiological relevance and might contribute to systemic ef-
fects in tissues such as the liver. Consequently, amorfrutin B
and related natural molecules might be considered partial pan-
PPAR agonists with potentially synergistic effects.
Dietary small molecules derived from food ingredients of
various cultures still represent a largely unexplored resource
for preventing or treating complex diseases such as insulin
resistance. The identification of the potent natural PPARγ-
activator amorfrutin B, which can be isolated in large quan-
tities from liquorice, highlights the medicinal potential of
natural dietary substances.
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